Filtered By:
Condition: Pain
Vaccination: Vaccines
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 92 results found since Jan 2013.
New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
'More adults should be taking statins,' says NICE
Conclusion
Despite somewhat hysterical media coverage to the contrary ("millions more to be given statins," according to the Daily Express), nobody will be forced to take statins.
If your GP does recommend statins, you should ask them to explain the benefits and risks for you personally of starting statin treatment. You may want to find out more about statins before making up your mind – the NHS Choices Health A-Z information on statins is a good place to start.
If you do experience troublesome side effects while taking statins, contact your GP or the doctor in charge of your care. It could be the case that a...
Source: NHS News Feed - July 18, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Will a cholesterol-busting vaccine work for humans?
Conclusion
The first thing to keep in mind is this is an early-stage study in the development of a vaccine to lower cholesterol. The study found some of the experimental vaccines the researchers developed had an effect on the cholesterol levels of mice and monkeys to varying degrees.
They now need to do further work to show the vaccine is effective and can be used safely in humans. Many drugs have very different effects in humans than they do in other animals.
The use of statins to lower cholesterol and reduce the chances of a heart attack or stroke is well established and effective for many people. Although there is ongo...
Source: NHS News Feed - November 12, 2015 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
Developments in Varicella Zoster Virus Vasculopathy
Abstract
Varicella zoster virus (VZV) is a highly neurotropic human herpesvirus. Primary infection usually causes varicella (chicken pox), after which virus becomes latent in ganglionic neurons along the entire neuraxis. VZV reactivation results in zoster (shingles) which is frequently complicated by chronic pain (postherpetic neuralgia). VZV reactivation also causes meningoencephalitis, myelitis, ocular disorders, and vasculopathy, all of which can occur in the absence of rash. This review focuses on the association of VZV and stroke, and on the widening spectrum of disorders produced by VZV vasculopathy in immu...
Source: Current Neurology and Neuroscience Reports - January 11, 2016 Category: Neuroscience Source Type: research
157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June:
Accurate Results in the Clinical Laboratory
Adult Emergency Medicine
Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.)
Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.)
Advancing Your Career: Concepts of Professional Nursing (5th ed.)
Arrhythmia Essentials
Atlas of Advanced Operative Surgery
Atlas of Clinical Neurology (3rd ed.)
Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches
Atlas of Human Infectious Diseases
Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news
What a jerk: perils in the assessment of psychogenic movement disorders
In 2012, the upstate New York town of LeRoy became something of a neuropsychiatric battleground when it witnessed an outbreak of cases of sudden-onset tic-like behaviour in high-school age girls, many from a single school.1 The ‘Tourette's epidemic’, as it was dubbed by a fascinated world media, attracted different explanations: for every claim that this was ‘mass hysteria’ (ie, conversion disorder), there was an outraged counter-claim to the effect that such a diagnosis was missing a real organic cause of these tics and jerks, variously thought to be PANDAS (a rare and still controversial apparent ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - July 8, 2013 Category: Neurosurgery Authors: Pollak, T. A. Tags: Genetics, Immunology (including allergy), Epilepsy and seizures, Movement disorders (other than Parkinsons), Neurological injury, Pain (neurology), Stroke, Trauma CNS / PNS, Child and adolescent psychiatry, Memory disorders (psychiatry), Somatoform disord Source Type: research
Treatment of Post-Influenza Vaccination Induced Acute Disseminated Encephalomyelitis (ADEM) with Plasma Exchange - A Case Report (P4.036)
DISCUSSION:Influenza vaccination has been rarely linked to ADEM. Due to a low-incidence of the disease, there are no established treatment guidelines. Our patient did not respond to steroids but showed marked radiographic improvement with PE. PE should be considered for refractory ADEM after influenza vaccination.Disclosure: Dr. Chahil has nothing to disclose. Dr. Pillainayagam has nothing to disclose. Dr. Schulz has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Chahil, M., Pillainayagam, C., Schulz, P. Tags: General Neurology III Source Type: research
Management of Sickle Cell Disease: Recommendations from the 2014 Expert Panel Report.
Abstract
Family physicians are the primary and sometimes only health care resource for families affected by sickle cell disease. Recently published guidelines provide important recommendations for health maintenance, acute care, and monitoring of disease-modifying therapy in persons with this condition. This overview highlights some of the most important clinical activities that can and should be carried out in the community care setting. Children with sickle cell anemia should receive prophylactic penicillin from birth through at least five years of age, and all persons with sickle cell disease require vaccinatio...
Source: American Family Physician - December 15, 2015 Category: Primary Care Authors: Yawn BP, John-Sowah J Tags: Am Fam Physician Source Type: research
Don’t shrug off shingles
If you had chickenpox as a kid, there is a good chance you may develop shingles later in life. “In fact, one in three is predicted to get shingles during their lifetime,” says Dr. Anne Louise Oaklander, director of the Nerve Unit at Harvard-affiliated Massachusetts General Hospital.
The same varicella-zoster virus that causes chickenpox also causes shingles. After the telltale spots of chickenpox vanish, the virus lies dormant in your nerve cells near the spinal cord and brain. When your immunity weakens from normal aging or from illnesses or medications, the virus can re-emerge. It then travels along a nerve to trigge...
Source: New Harvard Health Information - February 18, 2016 Category: Consumer Health News Authors: Matthew Solan Tags: Healthy Aging Infectious diseases Vaccines Source Type: news
Why it ’ s a bad idea to space out your child ’ s vaccination shots
With so many vaccines being required for young children today, some parents are asking their doctors whether they can space out or delay the vaccine schedule. They’re concerned that too many vaccines might overwhelm their child's immune system. Parents also worry that getting more than one shot at a time increases the pain and stress. Debate […]Related:Stroke rates appear to be rising steadily in young adultsCalifornia vaccination rate hits new high after tougher immunization lawRisk of a rare but deadly mouse-borne virus increases in the spring
Source: Washington Post: To Your Health - April 17, 2017 Category: Consumer Health News Source Type: news
Emergency Department Intervention May Reduce Suicide Attempts in At-Risk Patients
Astudy published April 29 inJAMA Psychiatry reports that a multifaceted intervention incorporating screening, safety planning guidance, and periodic telephone follow-up can reduce the risk of suicidal behavior in at-risk individuals who present in the emergency department (ED).The reductions were modest but clinically significant; compared with usual ED treatment, the number of patients who attempted suicide dropped by about 20% and the total number of suicide attempts dropped by about 30%.“We would like to have had an even stronger effect, but the fact that we were able to impact attempts with this population and w...
Source: Psychiatr News - May 2, 2017 Category: Psychiatry Tags: emergency department suicidal risk suicide prevention suicide screening Source Type: research
A True Hematologic Emergency
BY GREGORY TAYLOR, DO, & JACKLYN MCPARLANE, DOA 33-year-old woman with a past medical history of sickle cell SS presented to the emergency department with chest pain, difficulty breathing, and a cough for two days. Her chest pain was diffuse, without radiation, and partially reproducible. Her cough was nonproductive, and she also reported fever and chills.The patient noted this was different from her normal back and leg pain from past sickle cell crises. She was following up with a sickle cell specialist, and was compliant with her hydroxyurea treatment.Her temperature was 102.8°F, blood pressure was 94/60 mm...
Source: The Case Files - June 26, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
